Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of XBI-302 in Healthy Volunteers
NCT05352269Phase 1Unknown
- Sponsor
- Xbiome
- Start
- Apr 2022
- Primary completion
- Aug 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XBI-302 in Acute Graft-Versus-Host Disease (aGvHD) (8 cohorts), sponsored by Xbiome. Primary endpoint: Incidence and severity of all AEs and SAEs at Day 28. Status: unknown.
02
Drugs
XBI-302
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05352269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352269.